# Doctoral Dissertation Research Proposal

**Project Title:** Rewiring the Circadian Gating of *Akkermansia muciniphila* Live Biotherapeutic Colonization and Metabolic Efficacy by Host Lifestyles: A Mechanistic Closed-Loop Integrating Multi-Omics and Structural Macromolecular Models  
**Major:** Biostatistics / Computational Genomics and Bioinformatics  
**Research Direction:** Gut Microenvironment & Translational Medicine, AI for Science (AI4S)  

---

## Abstract

Next-generation probiotics (NGPs), particularly *Akkermansia muciniphila* (AKK), have emerged as revolutionary translational entities for mitigating obesity, insulin resistance, and systemic metabolic syndromes. A milestone clinical trial published in *Nature Medicine* (Mount et al., May 2026) demonstrated that supplementing pasteurized AKK (*MucT®*) significantly suppresses weight regain in individuals with obesity post-dietary intervention. However, it simultaneously unveiled a profound inter-individual heterogeneity in clinical outcomes. Currently, the bottleneck obstructing the precise clinical translation of live AKK formulations lies in our lack of causal understanding regarding how highly dynamic host lifestyles (e.g., westernized diets, sleep deprivation, and circadian misalignment) act as upstream master variables to "gatekeep" the colonization kinetics and transcriptional activities of introduced live biotherapeutics.

This project pioneers an interdisciplinary paradigm combining *in vivo/in vitro* wet-lab validation with data-driven *in silico* AI modeling. First, we will establish a mouse cross-intervention framework to phenotypically map how high-fat, high-sucrose diets and chronic sleep deprivation abrogate the therapeutic efficacy of live AKK. Spatial-temporal colonization kinetics will be tracked using time-resolved absolute qPCR and fluorescence in situ hybridization (FISH) within the colonic niche. Second, metatranscriptomics and single-cell RNA sequencing (scRNA-seq) will be deployed to elucidate how lifestyle-driven disruption of host goblet cells' mucin-2 (MUC2) secretion clock rewires the transcriptional switches of exogenous AKK. Crucially, we will leverage **AlphaFold 3** (an all-atom macromolecular structure foundation model) and **Geneformer** (a cell state transformer model) to predict the binding structural physics between key AKK outer-membrane proteins (e.g., Amuc_1100 orthologs) and host epithelial receptors (e.g., TLR2) under shifting chemical microenvironments. These computational predictions will be validated via hard causal loops utilizing $Tlr2^{-/-}$ and intestinal epithelial-specific $Bmal1^{-/-}$ knock-out mice. Finally, we will train machine learning architectures (XGBoost/MLP) on multidimensional human clinical profiles to construct a high-precision classifier predicting "Responder" phenotypes. This work aims to provide a mechanistic blueprint and personalized lifestyle guidelines for optimizing next-generation live biotherapeutic interventions.

---

## 1. Introduction & Significance

### 1.1 Clinical Landscape and Bottlenecks of Next-Generation Live Biotherepeutics
Obesity and its associated metabolic co-morbidities represent an escalating global public health crisis. Although GLP-1 receptor agonists (e.g., semaglutide, orforglipron) have revolutionized weight loss therapy, their prohibitive costs, gastrointestinal adverse effects, and inevitable weight rebound upon cessation make long-term weight maintenance an elusive target in metabolic medicine.

*Akkermansia muciniphila*, a strict anaerobe mucosal symbiont, has consistently exhibited strong inverse correlations with host adiposity, low-grade inflammation, and insulin resistance. In May 2026, *Nature Medicine* published two concurrent landmark papers. One large-scale double-blind RCT (Mount et al., *Nat Med*, 2026) confirmed that oral administration of pasteurized *Akkermansia muciniphila* MucT over 24 weeks effectively blunts weight regain during an unrestricted ad libitum maintenance phase by transcriptionally reprogramming adipose tissue oxidative pathways. However, this trial also highlighted a pervasive challenge in microbiome therapeutics: extreme **inter-individual variability**. A substantial subset of participants exhibited a "Non-responder" phenotype, gaining weight despite identical dosing. This strongly indicates that introduced live biotherapeutics do not operate in a static vacuum, but are subject to the host's highly dynamic physiological and behavioral matrix.

### 1.2 Host Lifestyles and Circadian Gating of the Gut Ecological Niche
The colonic mucus layer, principally composed of MUC2 glycoproteins secreted by goblet cells, serves as the exclusive ecological niche and carbon source for AKK. Chronobiology has established that the intestinal epithelium is under tight peripheral clock control governed by core clock loops (*Bmal1, Clock, Per1/2*), causing mucin synthesis, immune sampling, and bile acid profiles to oscillate in a strict circadian manner.

In modern society, high-fat, high-sugar diets coupled with sleep deprivation and shift-work disrupt these peripheral tissue clocks, causing them to uncouple from the central suprachiasmatic nucleus (SCN). Recent landmark studies have demonstrated that sleep deprivation leads to severe lysosomal deacidification in goblet cells, collapsing the intestinal mucus barrier (Wang et al., *Cell Host Microbe*, 2023). **However, a fundamental blind spot remains: how do disrupted host lifestyles and the resulting uncoupled tissue microenvironments causally gatekeep the chronological colonization kinetics, functional transcription, and clinical metabolic efficacy of freshly introduced exogenous live AKK?**

### 1.3 The Necessity of AI for Science (AI4S) in Microbiome Mechanics
Traditional microbiome research relies heavily on descriptive 16S rRNA sequencing. When faced with multi-omics datasets spanning temporal host behavior, bacterial metatranscriptomics, metabolomics, and host scRNA-seq, classical linear correlation frameworks inevitably lose non-linear regulatory features. With the advent of multi-chain macromolecular models (AlphaFold 3) and transformer-based cell foundation models (Geneformer, scGPT), researchers can now simulate all-atom interactions and predict complex cell network perturbations *in silico*. Integrating AI-driven inference with wet-lab validation has become the gold standard for high-impact biological discovery.

---

## 2. Research Objectives & Central Questions

### 2.1 Research Objectives
This project aims to bridge the gap between traditional wet-lab assays and computational biology by establishing a "Lifestyle control $\rightarrow$ Multi-omics alignment $\rightarrow$ Foundation model inference $\rightarrow$ Gnotobiotic closed-loop" framework. We seek to systematically map the causal cascade of how host diet and sleep habits orchestrate the survival and transcription of supplemented live AKK, and build a machine learning model to predict therapeutic responders, establishing a paradigm for precision microbiome translation.

### 2.2 Central Scientific Questions
1.  **Phenotypic Layer:** Through what macro-physiological axes do distinct dietary structures combined with sleep deprivation/circadian misalignment abrogate the anti-obesity and insulin-sensitizing efficacy of live AKK?
2.  **Colonization Layer:** How does lifestyle-induced clock uncoupling in host goblet cells alter the temporal colonization kinetics and biogeographical localization of introduced live AKK?
3.  **Molecular Mechanism Layer:** How do shifting chemical and immunological microenvironments prompt a "transcriptional rewiring" in live AKK? What structural physical perturbations occur at the interface of key AKK outer-membrane proteins and host receptors (e.g., TLR2)?
4.  **Translational Layer:** Can host multi-dimensional lifestyle profiles and baseline metrics alone predict live biotherapeutic efficacy in human cohorts using non-linear machine learning classifiers?

---

## 3. Research Content & Experimental Design

The project is structured into four highly integrated modules (Modules 1–4) designed to build an ironclad causal chain.

### 3.1 Module 1: Mapping the Phenotypic Blockade of AKK Efficacy by Host Lifestyles (*In Vivo*)
This module establishes controlled animal models to quantify the extent to which diet and sleep disruption interfere with live AKK therapeutics.

* **Animal Models & Cross-Intervention:** 8-week-old C57BL/6J male mice will be subjected to a 2-factor (diet $\times$ circadian rhythm) cross-experimental layout for 12 weeks:
    * **Group 1 (Chow-Ctrl):** Standard chow diet + normal light-dark (12h:12h) cycle + vehicle (PBS).
    * **Group 2 (HFD-Vehicle):** 60% high-fat diet + normal LD cycle + vehicle.
    * **Group 3 (HFD-Healthy-AKK):** 60% high-fat diet + normal LD cycle + daily oral gavage of live *A. muciniphila* ($10^9$ CFU).
    * **Group 4 (HFD-DietShift-AKK):** Erratic/cafeteria diet (frequent shifts in fat/sugar ratios and feeding windows) + normal LD cycle + daily live AKK.
    * **Group 5 (HFD-SleepDep-AKK):** 60% high-fat diet + chronic sleep deprivation (using an automated sleep deprivation enclosure that provides gentle mechanical disruption during the daytime sleeping phase) + daily live AKK.
* **Metabolic Phenotyping:**
    * **Body Composition:** Longitudinal lean/fat mass tracking every two weeks via live EchoMRI.
    * **Glycemic Homeostasis:** Oral Glucose Tolerance Tests (OGTT) and Insulin Tolerance Tests (ITT) performed at weeks 8 and 12 to calculate the Area Under the Curve (AUC) and HOMA-IR indices.
    * **Systemic Inflammation:** Serum levels of endotoxin (LPS), TNF-$\alpha$, IL-6, and fasting active GLP-1 quantified via high-sensitivity ELISA.

### 3.2 Module 2: Temporal Colonization Kinetics and Spatial Biogeography of Live AKK
This module tracks the spatial-temporal journey of introduced live bacteria inside hostile or uncoupled host intestinal niches.

* **Temporal Clearance Dynamics:** Following a standardized single dose of live AKK at specific treatment phases, fecal samples will be collected at hyper-resolved time intervals (1h, 3h, 6h, 12h, 24h, 1w, 2w, 4w). Total metagenomic DNA will be extracted, and absolute quantification qPCR utilizing AKK-specific 16S rRNA primers will be performed to construct clearance kinetic models across the different lifestyle groups.
* **Spatial Niche Biogeography (FISH-IF):** Distal colon segments will be harvested using Carnoy's fixative to preserve the mucus architecture. Paraffin sections will undergo dual **Fluorescence In Situ Hybridization and Immunofluorescence (FISH-IF)** using a Cy3-conjugated AKK-specific 16S probe (5'-GGCTTGCTTGCTCGTGTG-3') combined with an FITC-labeled anti-MUC2 antibody. Using high-resolution confocal microscopy, we will map the absolute spatial distance of AKK cells relative to the epithelial border to determine whether sleep deprivation causes AKK to directly contact epithelial cells due to a depleted mucus layer, shifting its role from symbiotic to inflammatory.

### 3.3 Module 3: Multi-Omics Integration and Macromolecular Structural Modeling (*In Silico* & *In Vivo*)
This core module dissects the molecular mechanisms and structural biophysics using an AI4S pipeline.

* **Metatranscriptomics & Network Alignment:** Luminal content RNA will be extracted, depleted of host/ribosomal RNA, and subjected to deep sequencing. Focusing on the AKK transcriptome, we will employ a partial least squares regression framework (**mixOmics-PLS**) to align host lifestyle parameters and untargeted LC-MS/MS cecal metabolomics with AKK transcriptional pathways. We aim to discover whether sleep-deprived microenvironments force AKK to overexpress mucin-degrading glycoside hydrolases (over-eating the host barrier due to starvation) or suppress protective structural elements like the Amuc_1100 protein.
* **AlphaFold 3 Interactome Simulation:** The amino acid sequences of AKK outer-membrane components highlighted by metatranscriptomics will be entered into **AlphaFold 3**. We will simulate the all-atom structural docking of these bacterial proteins against host pattern recognition receptors (TLR2, TLR4) and endocrine L-cell receptors. This simulation will incorporate local chemical ligands (e.g., specific secondary bile acids discovered via metabolomics) to calculate binding free energies ($\Delta G$) and run in silico mutational scanning to identify critical binding pockets.
* **Geneformer Cell State Inference:** Single-cell RNA sequencing (scRNA-seq) will be performed on isolated colonic mucosal cells. The digital expression profiles will be used to fine-tune **Geneformer** (a 200M-parameter foundational single-cell transformer model). This model will simulate how host goblet cells' gene regulatory networks (GRNs) collapse under localized clock disruption, identifying upstream transcription factors that stall MUC2 O-glycosylation.
* **Causal Validation via Knock-out Models:**
    * **Receptor Genetic Causal Loop:** Global **`Tlr2` knock-out mice ($Tlr2^{-/-}$)** will be utilized. If a healthy lifestyle combined with live AKK fails to rescue HFD-induced insulin resistance in $Tlr2^{-/-}$ mice, it will confirm the computational model's receptor axis.
    * **Peripheral Clock Causal Loop:** Intestinal epithelial-specific **`Bmal1` knock-out mice ($Bmal1^{\Delta IEC}$)** will be generated via the *Vilin-Cre* system. These mice lack an independent gut epithelial clock. We will test whether $Bmal1^{\Delta IEC}$ mice under normal sleep conditions display the same live AKK non-responsiveness seen in sleep-deprived wild-type mice, establishing the peripheral tissue clock as the primary upstream gatekeeper.

### 3.4 Module 4: Human Gnotobiotic Validation and Machine Learning Response Classifiers
This translational module bridges mouse mechanics with human clinical applications, addressing the problem of clinical heterogeneity.

* **Humanized Gnotobiotic Mice (FMT):** Human volunteers will be stratified based on physiological telemetry from wearable devices (Oura Ring 4, Dexcom Stelo CGM):
    * **Cohort A (Healthy Lifestyles):** Highly consistent sleep architecture, high-polyphenol/high-fiber diets.
    * **Cohort B (Circadian Disrupted):** Chronic night-shift or late-sleep schedules, westernized high-fat convenience diets.
    * Fecal samples from Cohorts A and B will be transplanted into **Germ-Free (GF) mice**. Following humanization, both mouse cohorts will be fed identical HFD regimens and receive identical live AKK supplementation. This will test whether lifestyle-molded human donor microbiomes retain their gatekeeping effects across species lines.
* **Machine Learning Responder Predictor:** We will construct a clinical feature matrix $\mathbf{X}$ encompassing patient metrics (age, baseline AKK abundance, average sleep duration, sleep timing variability, dietary polyphenol scores). The target vector $Y$ will be binary metabolic responsiveness (Responder = 1, Non-responder = 0, defined by weight-loss maintenance efficacy).
    * We will train an optimized **XGBoost** classifier and a **Multilayer Perceptron (MLP)** network.
    * Using 5-fold cross-validation to minimize overfitting, we will evaluate performance using Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) metrics to deliver an actionable, lifestyle-informed precision prescription software tool for next-generation live biotherapeutics.

---

## 4. Expected Outcomes & Innovations

### 4.1 Expected Outcomes
1.  **High-Impact Publications:** High-quality, comprehensive research articles targeted for *Cell*, *Nature*, or *Science* (or elite sub-journals like *Nature Medicine*, *Cell Host & Microbe*).
2.  **Theoretical Breakthrough:** Establishing a new paradigm showing that host peripheral circadian clocks act as upstream structural gates regulating the spatial-temporal and transcriptional survival of exogenous live therapeutics.
3.  **Computational Deliverables:** An open-source AlphaFold 3-derived data repository mapping bacterial-host macromolecular interfaces, alongside a cross-platform machine learning software suite designed to predict probiotic responsiveness in clinical trials.

### 4.2 Key Innovations
* **Conceptual Integration:** Moving beyond static "dead cell" kinetics (such as Mount et al., 2026) or simple descriptive sequencing, this project links **macro-behavioral chronobiology with live bacterial transcriptomics** inside the host.
* **AI4S Paradigm Close-Loop:** AI foundation models (AlphaFold 3, Geneformer) serve as active engines driving mechanistic discovery. Rather than acting as descriptive tools, they predict precise binding pockets and network anomalies that are then validated using targeted knock-out animal lines.
* **Translational Pipeline:** Leveraging humanized germ-free models to replicate modern sleep/diet disruptions provides a direct path toward personalized clinical applications and medical software deployment.

---

## 5. Feasibility Analysis

1.  **Infrastructure & Platforms:** The laboratory features an advanced germ-free facility capable of executing large-scale humanized FMT trials under sterile conditions. High-resolution confocal, LC-MS/MS platforms, and single-cell libraries are fully operational.
2.  **Computational Resources:** The department maintains a high-performance GPU cluster (equipped with NVIDIA H100/A100 compute nodes) that natively supports local AlphaFold 3 structural simulations and large-scale transformer fine-tuning pipelines.
3.  **Technical Expertise:** The investigator possesses advanced proficiency in Python and R, with an established background in handling scRNA-seq processing, metatranscriptomic assemblies, and deep learning network configurations. Preliminary data on cell-to-cell communication networks ensure smooth execution of the multi-omics integration.

---

## 6. Timeline & Selected References

### Project Milestones
* **June 2026 – December 2026:** Finalize Module 1 animal cross-interventions; generate metabolic phenotypes; capture time-resolved qPCR clearance data and complete colonic FISH assays.
* **January 2027 – August 2027:** Complete metatranscriptomics and single-cell RNA-seq profiling. Launch AlphaFold 3 and Geneformer arrays; complete *in silico* docking simulations and lock in mutational target candidates.
* **September 2027 – March 2028:** Procure $Tlr2^{-/-}$ and $Bmal1^{\Delta IEC}$ breeding pairs; initiate back-validation wet-lab trials. Finalize human donor enrollment and initialize germ-free mouse humanization runs.
* **April 2028 – September 2028:** Complete machine learning classifier assembly and evaluate predictive performance. Consolidate figures, draft the final manuscript, and submit to leading journals.

### Selected References
1. Mount, S., Canfora, E. E., Jocken, J. W., ... & Blaak, E. E. (2026). Pasteurized *Akkermansia muciniphila* MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. *Nature Medicine*, 10.1038/s41591-026-04394-7.
2. Aronne, L. J., et al. (2026). Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. *Nature Medicine*, 10.1038/s41591-026-04386-7.
3. de Vos, W. M., Tilg, H., Van Hul, M., & Cani, P. D. (2022). Next-generation beneficial microbes: the case of *Akkermansia muciniphila*. *Frontiers in Microbiology*, 13, 1054.
4. Abramson, J., Adler, J., Dunger, J., ... & Jumper, J. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. *Nature*, 630, 493–500.
5. Theis, C. V., et al. (2023). Circadian rhythms clock the gut microbiota—host intersection in metabolic health. *Cell Host & Microbe*, 31(7), 1105-1118.
6. Wang, Z., et al. (2023). *Akkermansia muciniphila* ameliorates lysosomal deacidification in goblet cells to maintain the intestinal mucus barrier in sleep-deprived mice. *Cell Host & Microbe*, 31(11), 1821-1835. [https://doi.org/10.1016/j.chom.2023.10.005](https://doi.org/10.1016/j.chom.2023.10.005)